Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Allogene Therapeutics, Inc. (ALLO)
|
|
| Income Statement |
|
|
|
| Standardized | As Reported |
Annual | Quarterly | TTM |
|
| In millions, except per share items | Jun-30-23 | Jun-30-22 | Mar-31-22 | Dec-31-21 | Sep-30-21 | Jun-30-21 | Mar-31-21 | Dec-31-20 |
| | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K |
| Revenues | 0.0 | 0.1 | 0.1 | 0.1 | 0.0 | 0.0 | 38.3 | 0.0 |
| Revenue growth | -48.8% | 95.5% | -99.8% | | | | | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 0.0 | 0.1 | 0.1 | 0.1 | 0.0 | 0.0 | 38.3 | 0.0 |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Selling, general and administrative [+] | 18.5 | 19.5 | 19.9 | 20.0 | 19.0 | 18.8 | 16.4 | 17.1 |
| General and administrative | 18.5 | 19.5 | 19.9 | 20.0 | 19.0 | 18.8 | 16.4 | 17.1 |
| Research and development | 62.0 | 57.2 | 60.2 | 54.0 | 58.7 | 52.3 | 55.2 | 52.2 |
| EBITDA [+] | | -72.9 | -76.3 | -69.7 | -75.3 | -69.1 | -31.3 | -67.5 |
| EBITDA growth | 10.4% | 5.6% | 143.9% | 3.2% | 13.8% | 12.7% | -43.8% | 7.6% |
| EBITDA margin | -182995.5% | -84789.5% | -125082.0% | -136570.6% | -153755.1% | -156965.9% | -81.6% | |
| Depreciation and amortization | | 3.7 | 3.7 | 4.2 | 2.3 | 2.0 | 1.9 | 1.8 |
| EBIT [+] | -80.5 | -76.6 | -80.0 | -73.9 | -77.7 | -71.0 | -33.2 | -69.4 |
| EBIT growth | 5.1% | 7.8% | 140.9% | 6.5% | 14.2% | 12.5% | -42.4% | 7.4% |
| EBIT margin | -182995.5% | -89062.8% | -131134.4% | -144888.2% | -158510.2% | -161429.5% | -86.6% | |
| Interest income | 3.8 | 0.3 | | 1.7 | | 0.6 | | 9.2 |
| Interest income | 3.8 | 0.3 | | 1.7 | | 0.6 | | 9.2 |
| Other income (expense), net | -1.2 | 1.5 | 0.1 | -2.7 | -0.5 | -0.5 | 0.2 | -8.4 |
| Pre-tax income | -78.0 | -74.8 | -79.9 | -74.9 | -78.2 | -70.9 | -33.0 | -68.6 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -78.0 | -74.8 | -79.9 | -74.9 | -78.2 | -70.9 | -33.0 | -68.6 |
| Net margin | -177247.7% | -86961.6% | -130901.6% | -146800.0% | -159563.3% | -161218.2% | -86.1% | |
| |
| Basic EPS [+] | ($0.53) | ($0.52) | ($0.56) | ($0.55) | ($0.57) | ($0.53) | ($0.25) | ($0.57) |
| Growth | 1.9% | -0.9% | 126.1% | -3.2% | 9.6% | -0.4% | -50.0% | -5.7% |
| Diluted EPS [+] | ($0.53) | ($0.52) | ($0.56) | ($0.55) | ($0.57) | ($0.53) | ($0.25) | ($0.57) |
| Growth | 1.9% | -0.9% | 126.1% | -3.2% | 9.6% | -0.4% | -50.0% | -5.7% |
| |
| Shares outstanding (basic) [+] | 146.8 | 143.4 | 141.4 | 135.8 | 137.0 | 134.8 | 132.2 | 120.4 |
| Growth | 2.4% | 6.3% | 7.0% | 12.8% | 7.8% | 16.9% | 21.3% | 19.1% |
| Shares outstanding (diluted) [+] | 146.8 | 143.4 | 141.4 | 135.8 | 137.0 | 134.8 | 132.2 | 120.4 |
| Growth | 2.4% | 6.3% | 7.0% | 12.8% | 7.8% | 16.9% | 21.3% | 19.1% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|